Načítá se...
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
INTRODUCTION: Renal cell carcinoma (RCC) is a highly immunogenic neoplasm, and cytokine-based immunotherapies have been used for decades with limited success. In recent years, antibody-based immunotherapies targeting immune checkpoint receptors PD-1 and CTLA-4 have demonstrated clinical efficacy in...
Uloženo v:
| Vydáno v: | Expert Opin Biol Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6289271/ https://ncbi.nlm.nih.gov/pubmed/30124333 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2018.1513485 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|